The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291. Since the 2014 ASCO Annual Meeting, results have been updated to show that responses are durable – median PFS is 9.6 months. Currently, Galbraith says, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.

Galbraith also notes that AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.

The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291. Since the 2014 ASCO Annual Meeting, results have been updated to show that responses are durable – median PFS is 9.6 months. Currently, Galbraith says, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.

Galbraith also notes that AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.